Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
MOLECULARLY TARGETED: AKT mutation: myTACTIC Arm D(2)

myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: Arm D: Ipatasertib in patients with PTEN Loss/Loss-of-function or AKT activating mutation-positive tumors

Title
Genentech ML42439 (myTACTIC) AKT
Study Title

myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression pattersn predictive of response: Arm D: Ipatasertib in patients with PTEN Loss/Loss-of-function or AKT activating mutation-positive tumors

Site Link
Malignancy
Any: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
Any line
Investigational Agent
Ipatasertib
Drug Class
AKT inhibitor
PI
Axel Grothey, MD
Sponsor
Genentech, Inc.
Phase
Status
Key Eligibility Criteria
Key Eligibility Criteria Details
  • Histologically or cytologically confirmed advanced unresectable or metastatic solid malignancy
  • Positive biomarker results from a CLIA certified lab, either tissue or blood sample
  • One of the following mutations in AKT:
    • ​AKT 1 : E17K, L52R, or Q79K
    • AKT 2 : E17K
    • AKT 3: E17K, L51R, or Q78K
  • ECOG PS 0-2
  • No symptomatic CNS metastases
  • No known HIV/HBV/HCV
  • No other malignancy within 3 years of study
  • No prior treatment with crizotinib
  • No insulin dependent diabetes
Objective
  • Primary-
    • ORR
  • Secondary
    • PFS
    • DoR
    • OS
    • PFS at various time points
    • DCR
    • Safety
Assessment Frequency
_
Assessment Frequency 2
_



Assessment Frequency Link
Path
select AKT mutations
Dosing Frequency
Control Agents
Study Protocol
Randomized
No
X